CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3

TYK2 drugPositive
AI Analysis

Summary

Oak Hill Bio, a biotech focused on Angelman syndrome, merges with RA Capital's SPAC (Research Alliance Corporation III). InnoCare's TYK2 drug advances in Phase 3 clinical trials.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.40
SPAC mergerAngelman syndromePhase 3TYK2 inhibitor

Read the original article

Published by Endpoints News on July 28, 2026 3:17 PM

Read Original